State of New Jersey Common Pension Fund D purchased a new stake in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 40,898 shares of the company's stock, valued at approximately $2,370,000. State of New Jersey Common Pension Fund D owned about 0.08% of Astrana Health as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in the stock. GAMMA Investing LLC purchased a new position in shares of Astrana Health during the third quarter worth approximately $34,000. Nisa Investment Advisors LLC acquired a new stake in Astrana Health in the third quarter valued at $35,000. Central Pacific Bank Trust Division acquired a new stake in Astrana Health in the third quarter valued at $160,000. Everence Capital Management Inc. acquired a new stake in Astrana Health in the third quarter valued at $272,000. Finally, Granite Bay Wealth Management LLC acquired a new stake in Astrana Health in the third quarter valued at $290,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.
Astrana Health Trading Down 0.0 %
Shares of NASDAQ:ASTH traded down $0.01 during trading on Thursday, reaching $41.90. 432,617 shares of the stock were exchanged, compared to its average volume of 206,858. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.84 and a current ratio of 1.91. Astrana Health, Inc. has a 12-month low of $32.04 and a 12-month high of $63.20. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of 32.23, a price-to-earnings-growth ratio of 2.01 and a beta of 1.24. The firm's 50-day moving average price is $55.30 and its 200 day moving average price is $47.68.
Astrana Health (NASDAQ:ASTH - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The firm had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. During the same period in the previous year, the company posted $0.47 EPS. On average, sell-side analysts anticipate that Astrana Health, Inc. will post 1.16 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
ASTH has been the subject of several research reports. Truist Financial lifted their price target on Astrana Health from $50.00 to $59.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. TD Cowen initiated coverage on Astrana Health in a research report on Monday, October 14th. They set a "buy" rating and a $66.00 price objective for the company. KeyCorp initiated coverage on Astrana Health in a research report on Friday, October 11th. They set a "sector weight" rating for the company. BTIG Research lifted their price objective on Astrana Health from $60.00 to $70.00 and gave the stock a "buy" rating in a research report on Thursday, October 3rd. Finally, Stifel Nicolaus lifted their price target on Astrana Health from $48.00 to $60.00 and gave the company a "buy" rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $65.17.
Read Our Latest Stock Report on ASTH
Astrana Health Profile
(
Free Report)
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.
Featured Articles
Before you consider Astrana Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.
While Astrana Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
